COVID-19 vaccination recommendations have changed. See the latest recommendations.
Child and Adolescent Immunization Schedule by Age
To make vaccination recommendations, healthcare providers should:
- Determine needed vaccines based on age (Table 1)
- Determine appropriate intervals for catch-up, if needed (Table 2)
- Assess for medical conditions and other indications (Table 3)
- Review special situations (Vaccination Notes)
- Review contraindications and precautions to vaccination (Appendix)
Parent-friendly schedules
Vaccines your child may need: Get a personalized list of recommended vaccines
Legend
Range of recommended ages for all children | Range of recommended ages for catch-up vaccination |
Range of recommended ages for certain high-risk groups | Recommended vaccination can begin in this age group | Recommended vaccination based on shared clinical decision-making | No recommendation/Not applicable |
Birth to 15 Months
Vaccine | Birth | 1 mo | 2 mos | 4 mos | 6 mos | 9 mos | 12 mos | 15 mos |
---|---|---|---|---|---|---|---|---|
Hepatitis B ![]() (HepB) |
1st dose | ←2nd dose→ | ←3rd dose→ | |||||
Rotavirus ![]() (RV) RV1 (2-dose series); RV5 (3-dose series) |
1st dose | 2nd dose | See notes | |||||
Diphtheria, tetanus, & acellular pertussis ![]() (DTaP: <7 yrs) |
1st dose | 2nd dose | 3rd dose | ←4th dose→ | ||||
Haemophilus influenzae type b ![]() (Hib) |
1st dose | 2nd dose | See notes | ←3rd or 4th dose, See notes→ |
||||
Pneumococcal conjugate ![]() (PCV13, PCV15) |
1st dose | 2nd dose | 3rd dose | ←4th dose→ | ||||
Inactivated poliovirus ![]() (IPV: <18 yrs) |
1st dose | 2nd dose | ←3rd dose→ | |||||
COVID-19 ![]() (1vCOV-mRNA, 2vCOV-mRNA, 1vCOV-aPS) |
2- or 3-dose primary series and booster (See notes) |
|||||||
Influenza (IIV4) ![]() |
Annual vaccination 1 or 2 doses | |||||||
![]() Influenza (LAIV4) ![]() |
||||||||
Measles, mumps, rubella ![]() (MMR) |
See notes | ←1st dose→ | ||||||
Varicella ![]() (VAR) |
←1st dose→ | |||||||
Hepatitis A ![]() (HepA) |
See notes | ←2-dose series, See notes→ | ||||||
Tetanus, diphtheria, & acellular pertussis ![]() (Tdap: ≥7 yrs) |
||||||||
Human papillomavirus ![]() (HPV) |
||||||||
Meningococcal ![]() (MenACWY-D: ≥9 mos, MenACWY-CRM: ≥2 mos, MenACWY-TT: ≥2years) |
See notes | |||||||
Meningococcal B ![]() (MenB-4C, MenB-FHbp) |
||||||||
Pneumococcal polysaccharide ![]() (PPSV23) |
||||||||
Dengue ![]() (DEN4CYD: 9-16 yrs) |
18 Months to 18 Years
Vaccines | 18 mos |
19-23 mos |
2-3 yrs |
4-6 yrs |
7-10 yrs |
11-12 yrs |
13-15 yrs |
16 yrs |
17-18 yrs |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hepatitis B ![]() (HepB) |
←3rd dose→ | |||||||||||||||||||
Rotavirus ![]() (RV) RV1 (2-dose series); RV5 (3-dose series) |
||||||||||||||||||||
Diphtheria, tetanus, & acellular pertussis ![]() (DTaP: <7 yrs) |
←4th dose→ | 5th dose | ||||||||||||||||||
Haemophilus influenzae type b ![]() (Hib) |
||||||||||||||||||||
Pneumococcal conjugate ![]() (PCV13, PCV15) |
||||||||||||||||||||
Inactivated poliovirus ![]() (IPV: <18 yrs) |
←3rd dose→ | 4th dose | See notes |
|||||||||||||||||
COVID-19 ![]() (1vCOV-mRNA, 2vCOV-mRNA, 1vCOV-aPS) |
2- or 3- dose primary series and booster (See notes) | |||||||||||||||||||
Influenza (IIV4) ![]() |
Annual vaccination 1 or 2 doses | Annual vaccination 1 dose only | ||||||||||||||||||
![]() Influenza (LAIV4) ![]() |
Annual vaccination 1 or 2 doses
|
Annual vaccination 1 dose only | ||||||||||||||||||
Measles, mumps, rubella ![]() (MMR) |
2nd dose | |||||||||||||||||||
Varicella ![]() (VAR) |
2nd dose | |||||||||||||||||||
Hepatitis A ![]() (HepA) |
← 2-dose series, See notes→ | |||||||||||||||||||
Tetanus, diphtheria, & acellular pertussis ![]() (Tdap: ≥7 yrs) |
1 dose | |||||||||||||||||||
Human papillomavirus ![]() (HPV) |
See notes | |||||||||||||||||||
Meningococcal ![]() (MenACWY-D: ≥9 mos, MenACWY-CRM: ≥2 mos, MenACWY-TT: ≥2years) |
See notes | 1st dose | 2nd dose | |||||||||||||||||
Meningococcal B ![]() (MenB-4C, MenB-FHbp) |
See notes | |||||||||||||||||||
Pneumococcal polysaccharide ![]() (PPSV23) |
See notes | |||||||||||||||||||
Dengue ![]() (DEN4CYD: 9-16 yrs) |
Seropositive in endemic dengue areas (See notes) |
Administer recommended vaccines if immunization history is incomplete or unknown. Do not restart or add doses to vaccine series for extended intervals between doses. When a vaccine is not administered at the recommended age, administer at a subsequent visit. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.
Notes
For vaccination recommendations for persons ages 19 years or older, see the Recommended Adult Immunization Schedule, 2023.
Zusätzliche Informationen
- Consult relevant ACIP statements for detailed recommendations.
- For calculating intervals between doses, 4 weeks = 28 days. Intervals of ≥4 months are determined by calendar months.
- Within a number range (e.g., 12–18), a dash (–) should be read as “through.”
- Vaccine doses administered ≤4 days before the minimum age or interval are considered valid. Doses of any vaccine administered ≥5 days earlier than the minimum age or minimum interval should not be counted as valid and should be repeated as age-appropriate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. For further details, see Table 3-2, Recommended and minimum ages and intervals between vaccine doses, in General Best Practice Guidelines for Immunization.
- Information on travel vaccination requirements and recommendations is available at https://www.cdc.gov/travel/.
- For vaccination of persons with immunodeficiencies, see Table 8-1, Vaccination of persons with primary and secondary immunodeficiencies, in General Best Practice Guidelines for Immunization, Immunization in Special Clinical Circumstances (In: Kimberlin DW, Barnett ED, Lynfield Ruth, Sawyer MH, eds. Red Book: 2021–2024 Report of the Committee on Infectious Diseases. 32nd ed. Itasca, IL: American Academy of Pediatrics; 2021:72–86).
- For information about vaccination in the setting of a vaccine-preventable disease outbreak, contact your state or local health department.
- The National Vaccine Injury Compensation Program (VICP) is a no-fault alternative to the traditional legal system for resolving vaccine injury claims. All vaccines included in the child and adolescent vaccine schedule are covered by VICP except for dengue, PPSV23 and COVID-19 vaccines. COVID-19 vaccines that are authorized or approved by the FDA are covered by the Countermeasures Injury Compensation Program (CICP). For more information, see www.hrsa.gov/vaccinecompensation or www.hrsa.gov/cicp.
COVID-19 vaccination
(minimum age: 6 months [Moderna and Pfizer-BioNTech COVID-19 vaccines], 12 years [Novavax COVID-19 Vaccine])
COVID-19 vaccination recommendations have changed. See the latest recommendations.
Diphtheria, tetanus, and pertussis (DTaP) vaccination
(minimum age: 6 weeks [4 years for Kinrix® or Quadracel®])
Influenza vaccination
(minimum age: 6 months [IIV], 2 years [LAIV4], 18 years [recombinant influenza vaccine, RIV4])
Meningococcal serogroup A, C, W, Y vaccination (minimum age: 2 months [MenACWY-CRM, Menveo], 9 months [MenACWY-D, Menactra], 2 years [MenACWY-TT, MenQuadfi])
Meningococcal serogroup B vaccination
(minimum age: 10 years [MenB-4C, Bexsero®; MenB-FHbp, Trumenba®])
Tetanus, diphtheria, and pertussis (Tdap) vaccination
(minimum age: 11 years for routine vaccination, 7 years for catch-up vaccination)
Appendix - Guide to Contraindications and Precautions to Commonly Used Vaccines
Adapted from Table 4-1 in Advisory Committee on Immunization Practices (ACIP) General Best Practice Guidelines for Immunization: Contraindication and Precautions and ACIP’s Recommendations for the Prevention and Control of 2022-23 seasonal influenza with Vaccines.
For COVID-19 vaccine contraindications and precautions see www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#contraindications
Vaccine
Vaccine
Contraindicated or Not Recommended1
Contraindicated or Not Recommended1
Precautions2
Precautions2
- Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine (i.e., any egg-based IIV, ccIIV, RIV, or LAIV of any valency)
- Severe allergic reaction (e.g., anaphylaxis) to any vaccine component3 (excluding egg)
- Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine (i.e., any egg-based IIV, ccIIV, RIV, or LAIV of any valency)
- Severe allergic reaction (e.g., anaphylaxis) to any vaccine component3 (excluding egg)
- Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine
- Moderate or severe acute illness with or without fever
- Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine
- Moderate or severe acute illness with or without fever
- Severe allergic reaction (e.g., anaphylaxis) to any ccIIV of any valency, or to any component3 of ccIIV4
- Severe allergic reaction (e.g., anaphylaxis) to any ccIIV of any valency, or to any component3 of ccIIV4
- Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine
- Persons with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any egg-based IIV, RIV, or LAIV of any valency. If using ccIV4, administer in medical setting under supervision of healthcare provider who can recognize and manage severe allergic reactions. May consult an allergist.
- Moderate or severe acute illness with or without fever
- Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine
- Persons with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any egg-based IIV, RIV, or LAIV of any valency. If using ccIV4, administer in medical setting under supervision of healthcare provider who can recognize and manage severe allergic reactions. May consult an allergist.
- Moderate or severe acute illness with or without fever
- Severe allergic reaction (e.g., anaphylaxis) to any RIV of any valency, or to any component3 of RIV4
- Severe allergic reaction (e.g., anaphylaxis) to any RIV of any valency, or to any component3 of RIV4
- Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine
- Persons with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any egg- based IIV, ccIIV, or LAIV of any valency. If using RIV4, administer in medical setting under supervision of healthcare provider who can recognize and manage severe allergic reactions. May consult an allergist.
- Moderate or severe acute illness with or without fever
- Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine
- Persons with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any egg- based IIV, ccIIV, or LAIV of any valency. If using RIV4, administer in medical setting under supervision of healthcare provider who can recognize and manage severe allergic reactions. May consult an allergist.
- Moderate or severe acute illness with or without fever
- Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine (i.e., any egg-based IIV, ccIIV, RIV, or LAIV of any valency)
- Severe allergic reaction (e.g., anaphylaxis) to any vaccine component3 (excluding egg)
- Children age 2 – 4 years with a history of asthma or wheezing
- Anatomic or functional asplenia
- Immunocompromised due to any cause including medications and HIV infection
- Close contacts or caregivers of severely immunosuppressed persons who require a protected environment
- Pregnancy
- Cochlear implant
- Active communication between the cerebrospinal fluid (CSF) and the oropharynx, nasopharynx, nose, ear or any other cranial CSF leak
- Children and adolescents receiving aspirin or salicylate-containing medications
- Received influenza antiviral medications oseltamivir or zanamivir within the previous 48 hours, peramivir within the previous 5 days, or baloxavir within the previous 17 days
- Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine (i.e., any egg-based IIV, ccIIV, RIV, or LAIV of any valency)
- Severe allergic reaction (e.g., anaphylaxis) to any vaccine component3 (excluding egg)
- Children age 2 – 4 years with a history of asthma or wheezing
- Anatomic or functional asplenia
- Immunocompromised due to any cause including medications and HIV infection
- Close contacts or caregivers of severely immunosuppressed persons who require a protected environment
- Pregnancy
- Cochlear implant
- Active communication between the cerebrospinal fluid (CSF) and the oropharynx, nasopharynx, nose, ear or any other cranial CSF leak
- Children and adolescents receiving aspirin or salicylate-containing medications
- Received influenza antiviral medications oseltamivir or zanamivir within the previous 48 hours, peramivir within the previous 5 days, or baloxavir within the previous 17 days
- Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine
- Asthma in persons aged 5 years old or older
- Persons with underlying medical conditions (other than those listed under contraindications) that might predispose to complications after wild-type influenza virus infection [e.g., chronic pulmonary, cardiovascular (except isolated hypertension), renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus)]
- Moderate or severe acute illness with or without fever
- Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine
- Asthma in persons aged 5 years old or older
- Persons with underlying medical conditions (other than those listed under contraindications) that might predispose to complications after wild-type influenza virus infection [e.g., chronic pulmonary, cardiovascular (except isolated hypertension), renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus)]
- Moderate or severe acute illness with or without fever
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
- Severe immunodeficiency (e.g., hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long- term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised)
- Lack of laboratory confirmation of a previous Dengue infection
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
- Severe immunodeficiency (e.g., hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long- term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised)
- Lack of laboratory confirmation of a previous Dengue infection
- Pregnancy
- HIV infection without evidence of severe immunosuppression
- Moderate or severe acute illness with or without fever
- Pregnancy
- HIV infection without evidence of severe immunosuppression
- Moderate or severe acute illness with or without fever
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
- For DTaP only: Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) not attributable to another identifiable cause within 7 days of administration of previous dose of DTP or DTaP
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
- For DTaP only: Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) not attributable to another identifiable cause within 7 days of administration of previous dose of DTP or DTaP
- Guillain-Barré syndrome (GBS) within 6 weeks after previous dose of tetanus-toxoid–containing vaccine
- History of Arthus-type hypersensitivity reactions after a previous dose of diphtheria-toxoid— containing or tetanus-toxoid– containing vaccine; defer vaccination until at least 10 years have elapsed since the last tetanus-toxoid- containing vaccine
- For DTaP only: Progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, progressive encephalopathy; defer DTaP until neurologic status clarified and stabilized
- Moderate or severe acute illness with or without fever
- Guillain-Barré syndrome (GBS) within 6 weeks after previous dose of tetanus-toxoid–containing vaccine
- History of Arthus-type hypersensitivity reactions after a previous dose of diphtheria-toxoid— containing or tetanus-toxoid– containing vaccine; defer vaccination until at least 10 years have elapsed since the last tetanus-toxoid- containing vaccine
- For DTaP only: Progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, progressive encephalopathy; defer DTaP until neurologic status clarified and stabilized
- Moderate or severe acute illness with or without fever
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
- For Hiberix, ActHib, and PedvaxHIB only: History of severe allergic reaction to dry natural latex
- Age <6 weeks
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
- For Hiberix, ActHib, and PedvaxHIB only: History of severe allergic reaction to dry natural latex
- Age <6 weeks
- Moderate or severe acute illness with or without fever
- Moderate or severe acute illness with or without fever
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3 including neomycin
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3 including neomycin
- Moderate or severe acute illness with or without fever
- Moderate or severe acute illness with or without fever
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3 including yeast
- Pregnancy: Heplisav-B and PreHevbrio are not recommended due to lack of safety data in pregnant persons. Use other hepatitis B vaccines if HepB is indicated.
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3 including yeast
- Pregnancy: Heplisav-B and PreHevbrio are not recommended due to lack of safety data in pregnant persons. Use other hepatitis B vaccines if HepB is indicated.
- Moderate or severe acute illness with or without fever
- Moderate or severe acute illness with or without fever
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3 including neomycin and yeast
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3 including neomycin and yeast
- Moderate or severe acute illness with or without fever
- Moderate or severe acute illness with or without fever
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
- Pregnancy: HPV vaccination not recommended.
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
- Pregnancy: HPV vaccination not recommended.
- Moderate or severe acute illness with or without fever
- Moderate or severe acute illness with or without fever
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
- Severe immunodeficiency (e.g., hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised)
- Pregnancy
- Family history of altered immunocompetence, unless verified clinically or by laboratory testing as immunocompetent
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
- Severe immunodeficiency (e.g., hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised)
- Pregnancy
- Family history of altered immunocompetence, unless verified clinically or by laboratory testing as immunocompetent
- Recent (≤11 months) receipt of antibody-containing blood product (specific interval depends on product)
- History of thrombocytopenia or thrombocytopenic purpura
- Need for tuberculin skin testing or interferon-gamma release assay (IGRA) testing
- Moderate or severe acute illness with or without fever
- For MMRV only: Personal or family (i.e., sibling or parent) history of seizures of any etiology
- Recent (≤11 months) receipt of antibody-containing blood product (specific interval depends on product)
- History of thrombocytopenia or thrombocytopenic purpura
- Need for tuberculin skin testing or interferon-gamma release assay (IGRA) testing
- Moderate or severe acute illness with or without fever
- For MMRV only: Personal or family (i.e., sibling or parent) history of seizures of any etiology
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
- For MenACWY-D and Men ACWY-CRM only: severe allergic reaction to any diphtheria toxoid– or CRM197–containing vaccine
- For MenACWY-TT only: severe allergic reaction to a tetanus toxoid-containing vaccine
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
- For MenACWY-D and Men ACWY-CRM only: severe allergic reaction to any diphtheria toxoid– or CRM197–containing vaccine
- For MenACWY-TT only: severe allergic reaction to a tetanus toxoid-containing vaccine
- For MenACWY-CRM only: Preterm birth if less than age 9 months
- Moderate or severe acute illness with or without fever
- For MenACWY-CRM only: Preterm birth if less than age 9 months
- Moderate or severe acute illness with or without fever
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
- Pregnancy
- For MenB-4C only: Latex sensitivity
- Moderate or severe acute illness with or without fever
- Pregnancy
- For MenB-4C only: Latex sensitivity
- Moderate or severe acute illness with or without fever
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
- Severe allergic reaction (e.g., anaphylaxis) to any diphtheria-toxoid– containing vaccine or its component3
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
- Severe allergic reaction (e.g., anaphylaxis) to any diphtheria-toxoid– containing vaccine or its component3
- Moderate or severe acute illness with or without fever
- Moderate or severe acute illness with or without fever
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
- Moderate or severe acute illness with or without fever
- Moderate or severe acute illness with or without fever
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
- Pregnancy
- Moderate or severe acute illness with or without fever
- Pregnancy
- Moderate or severe acute illness with or without fever
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
- Severe combined immunodeficiency (SCID)
- History of intussusception
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
- Severe combined immunodeficiency (SCID)
- History of intussusception
- Altered immunocompetence other than SCID
- Chronic gastrointestinal disease
- RV1 only: Spina bifida or bladder exstrophy
- Moderate or severe acute illness with or without fever
- Altered immunocompetence other than SCID
- Chronic gastrointestinal disease
- RV1 only: Spina bifida or bladder exstrophy
- Moderate or severe acute illness with or without fever
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
- For Tdap only: Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) not attributable to another identifiable cause within 7 days of administration of previous dose of DTP, DTaP, or Tdap
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
- For Tdap only: Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) not attributable to another identifiable cause within 7 days of administration of previous dose of DTP, DTaP, or Tdap
- Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of tetanus-toxoid–containing vaccine
- History of Arthus-type hypersensitivity reactions after a previous dose of diphtheria-toxoid— containing or tetanus-toxoid– containing vaccine; defer vaccination until at least 10 years have elapsed since the last tetanus-toxoid– containing vaccine
- For Tdap only: Progressive or unstable neurological disorder, uncontrolled seizures, or progressive encephalopathy until a treatment regimen has been established and the condition has stabilized
- Moderate or severe acute illness with or without fever
- Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of tetanus-toxoid–containing vaccine
- History of Arthus-type hypersensitivity reactions after a previous dose of diphtheria-toxoid— containing or tetanus-toxoid– containing vaccine; defer vaccination until at least 10 years have elapsed since the last tetanus-toxoid– containing vaccine
- For Tdap only: Progressive or unstable neurological disorder, uncontrolled seizures, or progressive encephalopathy until a treatment regimen has been established and the condition has stabilized
- Moderate or severe acute illness with or without fever
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
- Severe immunodeficiency (e.g., hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long- term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised)
- Pregnancy
- Family history of altered immunocompetence, unless verified clinically or by laboratory testing as immunocompetent
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
- Severe immunodeficiency (e.g., hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long- term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised)
- Pregnancy
- Family history of altered immunocompetence, unless verified clinically or by laboratory testing as immunocompetent
- Recent (≤11 months) receipt of antibody-containing blood product (specific interval depends on product)
- Receipt of specific antiviral drugs (acyclovir, famciclovir, or valacyclovir) 24 hours before vaccination (avoid use of these antiviral drugs for 14 days after vaccination)
- Use of aspirin or aspirin-containing products
- Moderate or severe acute illness with or without fever
- If using MMRV, see MMR/MMRV for additional precautions
- Recent (≤11 months) receipt of antibody-containing blood product (specific interval depends on product)
- Receipt of specific antiviral drugs (acyclovir, famciclovir, or valacyclovir) 24 hours before vaccination (avoid use of these antiviral drugs for 14 days after vaccination)
- Use of aspirin or aspirin-containing products
- Moderate or severe acute illness with or without fever
- If using MMRV, see MMR/MMRV for additional precautions
- When a contraindication is present, a vaccine should NOT be administered. Kroger A, Bahta L, Hunter P. ACIP General Best Practice Guidelines for Immunization.
- When a precaution is present, vaccination should generally be deferred but might be indicated if the benefit of protection from the vaccine outweighs the risk for an adverse reaction. Kroger A, Bahta L, Hunter P. ACIP General Best Practice Guidelines for Immunization.
- Vaccination providers should check FDA-approved prescribing information for the most complete and updated information, including contraindications, warnings, and precautions. See Package inserts for U.S.-licensed vaccines.
- For information on the pregnancy exposure registries for persons who were inadvertently vaccinated with Heplisav-B or PreHevbrio while pregnant, please visit heplisavbpregnancyregistry.com/ or www.prehevbrio.com/#safety.
Vaccines in the Child and Adolescent Immunization Schedule*
Vaccines | Abbreviation(s) | Trade name(s) |
---|---|---|
COVID-19 | 1vCOV-mRNA | Comirnaty®/Pfizer- BioNTech COVID-19 Vaccine |
SPIKEVAX®/Moderna COVID-19 Vaccine | ||
2vCOV-mRNA | Pfizer-BioNTech COVID-19 Vaccine, Bivalent | |
Moderna COVID-19 Vaccine, Bivalent | ||
1vCOV-aPS | Novavax COVID-19 Vaccine | |
Dengue vaccine | DEN4CYD | Dengvaxia® |
Diphtheria, tetanus, and acellular pertussis vaccine | DTaP | Daptacel® Infanrix® |
Diphtheria, tetanus vaccine | DT | No Trade Name |
Haemophilus influenzae type B vaccine | Hib (PRP-T) | ActHIB® Hiberix® |
Hib (PRP-OMP) | PedvaxHIB® | |
Hepatitis A vaccine | HepA | Havrix® Vaqta® |
Hepatitis B vaccine | HepB | Engerix-B® Recombivax HB® |
Human papillomavirus vaccine | HPV | Gardasil 9® |
Influenza vaccine (inactivated) | IIV4 | Multiple |
Influenza vaccine (live, attenuated) | LAIV4 | FluMist® Quadrivalent |
Measles, mumps, and rubella vaccine | MMR | M-M-R II® Priorix® |
Meningococcal serogroups A, C, W, Y vaccine | MenACWY-D | Menactra® |
MenACWY-CRM | Menveo® | |
MenACWY-TT | MenQuadfi® | |
Meningococcal serogroup B vaccine | MenB-4C | Bexsero® |
MenB-FHbp | Trumenba® | |
Pneumococcal conjugate vaccine | PCV13 | Prevnar 13® |
PCV15 | Vaxneuvance™ | |
Pneumococcal polysaccharide vaccine | PPSV23 | Pneumovax 23® |
Poliovirus vaccine (inactivated) | IPV | IPOL® |
Rotavirus vaccine | RV1 RV5 |
Rotarix® RotaTeq® |
Tetanus, diphtheria, and acellular pertussis vaccine | Tdap | Adacel® Boostrix® |
Tetanus and diphtheria vaccine | Td | Tenivac® TDvax™ |
Varicella vaccine | VAR | Varivax® |
Combination Vaccines
(Use combination vaccines instead of separate injections when appropriate)
Vaccines | Abbreviation(s) | Trade name(s) |
---|---|---|
DTaP, hepatitis B, and inactivated poliovirus vaccine | DTaP-HepB-IPV | Pediarix® |
DTaP, inactivated poliovirus, and Haemophilus influenzae type B vaccine | DTaP-IPV/Hib | Pentacel® |
DTaP and inactivated poliovirus vaccine | DTaP-IPV | Kinrix® Quadracel® |
DTaP, inactivated poliovirus, Haemophilus influenzae type b, and hepatitis B vaccine | DTaP-IPV-Hib-HepB | Vaxelis® |
Measles, mumps, rubella, and varicella vaccines | MMRV | ProQuad® |
* Administer recommended vaccines if immunization history is incomplete or unknown. Do not restart or add doses to vaccine series for extended intervals between doses. When a vaccine is not administered at the recommended age, administer at a subsequent visit. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.
This schedule is recommended by the Advisory Committee on Immunization Practices (ACIP) and approved by the Centers for Disease Control and Prevention (CDC), American Academy of Pediatrics (AAP), American Academy of Family Physicians (AAFP), American College of Obstetricians and Gynecologists (ACOG), American College of Nurse-Midwives (ACNM), American Academy of Physician Associates (AAPA), and National Association of Pediatric Nurse Practitioners (NAPNAP).
Bericht
- Suspected cases of reportable vaccine-preventable diseases or outbreaks to your state or local health department
- Clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.govexternal icon or (800-822-7967)
Questions or comments
Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays.
Helpful information
- Complete Advisory Committee on Immunization Practices (ACIP) recommendations
- General Best Practice Guidelines for Immunization
- Vaccine information statements
- Outbreak information (including case identification and outbreak response), see Manual for the Surveillance of Vaccine-Preventable Diseases
- ACIP Shared Clinical Decision-Making Recommendations